TABLE 2.

In vitro activities of tenofovir, adefovir, and lamivudine against HBV, isolated from two patients, encoding the adefovir resistance mutation rtN236T

Patient no. and drug	Pretherapya,b		Posttherapyb		Fold change
	EC50	n	EC50	n
Patient 1
Tenofovir	0.33 ± 0.11	7	1.01 ± 0.84	8	3.0
Adefovir	0.26 ± 0.17	7	3.64 ± 2.78	8	13.8c
Lamivudine	0.04 ± 0.01	3	0.12 ± 0.06	3	3.5c
Patient 2
Tenofovir	0.13 ± 0.03	2	0.55 ± 0.07	5	4.2
Adefovir	0.21 ± 0.01	6	1.55 ± 0.91	7	7.3
Lamivudine	0.03 ± 0.02	3	0.07 ± 0.2	5	2.3

^aPretherapy isolates were confirmed not to contain rtN236T.

^bMean ± standard deviation from the indicated number of independent experiments (n).

^cPreviously reported (1).